Numerate, a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, has formed a multi-year agreement with Takeda under which Numerate will identify and deliver multiple clinical candidates. Numerate will drive discovery programs aimed at identifying clinical candidates for use in Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders. The projects will rely on Numerate levera...